**Glossary**

**Terms Related to Chugai's Business**

**Unmet medical need**
Medical need that is not adequately met due to a lack of effective treatments.

**First-in-class**
An original drug that is highly novel and useful, and will significantly change the therapeutic system.

**Best-in-class**
A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target.

**Development pipeline**
At pharmaceutical companies, refers to drug candidates that are being developed.

**Proof of Concept (PoC)/Early PoC**
Proof of concept (PoC) is confirmation that the therapeutic effect conceived in the research stage is effective in humans. Early PoC means that in addition to safety, signs of efficacy or pharmacological effect have been confirmed in a limited number of cases.

**Clinical trial**
A study to verify the safety, efficacy and other characteristics of a drug in human subjects. Studies conducted for the purpose of filing an application for approval are called clinical trials.

**Phase I**
Performed on a small number of healthy volunteers (or, for certain disease areas and diseases, on patients) to assess the drug’s safety and the process by which it is absorbed, distributed, metabolized and eliminated by the body.

**Phase II**
Performed on a small number of consenting patients to determine the safest and most effective dosage and the dosing regimen.

**Phase III**
Performed on a large number of consenting patients to verify the efficacy and safety of the new drug in comparison with existing drugs or placebo.

**Phase IV**
Post-marketing clinical surveillance. Performed on a larger number of consenting patients than in phase III studies to verify the drug’s safety and efficacy for its approved indication(s).

**Application for approval**
An application submitted by a pharmaceutical company to a regulatory agency to obtain approval for manufacturing and marketing of a new drug after its efficacy and safety have been verified in clinical trials. In Japan, the Minister of Health, Labour and Welfare (MHLW) grants manufacturing and marketing approval to substances deemed appropriate as pharmaceuticals based on reviews by the Pharmaceutical Affairs and Medical Devices Agency as well as academic and other experts in the Pharmaceutical Affairs and Food Sanitation Council.

**Additional indication**
A new indication for a previously approved drug.

**Lifecycle management**
The various measures taken to maximize the potential value of a drug, including shortening development time, expanding sales, extending the product’s life, and conducting appropriate cost control.

**Personalized Healthcare**
Even when a particular disease is treated with the same drug, there may be differences in the efficacy and side effects of that drug depending on the patient. One of the causes is thought to be that the genetic information related to the disease is different in each patient. Personalized healthcare (PHC) is an approach that focuses on these genetic-level differences to provide treatment tailored to the characteristics of each patient’s disease. It therefore brings significant benefits in terms of efficiency, safety and cost effectiveness.

**Cancer Genomic Medicine**
One example of PHC. Medical treatment that measures multiple cancer-related genes in a single test using gene panel examination and performs optimal treatment according to each patient’s genomic profile.

**Biopharmaceuticals**
Drugs created by applying biotechnology such as genetic recombination. In the 1980s, when rapid advances were made in genetic engineering, Chugai decided to shift to research and development of biopharmaceuticals and made related large-scale capital investments.

**Therapeutic antibody**
A type of biopharmaceutical, it is an artificially created antibody used as a medicine to prevent or treat diseases. Therapeutic antibodies are designed to act only on the specific molecule (antigen) that causes the disease, and therefore can be expected to provide high therapeutic efficacy and reduce side effects. Chugai launched the first therapeutic antibody created in Japan in 2005, and is leading the world with its proprietary antibody engineering technologies.

**Modality**
In the pharmaceutical industry, refers to the material classification of a medicine. Until the 1990s, small molecule drugs were virtually the only modality, but the options are now increasing. New modalities enable new approaches to diseases that have no effective treatment methods. Chugai is focusing on establishing middle molecules as a third modality, in addition to its biologics and small molecules.

**Open innovation**
Generating innovative value by utilizing the technologies and development capabilities of external research networks such as universities, research institutions and other organizations.

**Translational Research**
Research that builds a bridge between the findings of basic research by academia and the development of new medicines by pharmaceutical companies.

**Work-life synergy (Work-life balance)**
Chugai’s work-life synergy aims to generate a synergistic effect that brings forth motivation, vitality and innovation by enhancing both work and the lives of individuals. Work-life synergy, an advancement of the concept of work-life balance, is necessary for a fulfilling personal life, as well as for becoming the top innovator in the healthcare industry.

**Diversity and Inclusion**
At Chugai, diversity refers to a diversity of attributes such as gender, age and nationality, as well as ways of thinking, values and experience. Inclusion refers to the state of respecting each other’s differences and the ability of everyone to contribute and perform at his or her full potential. When people with various backgrounds work together, they become aware of diverse perspectives and ideas. Companies promote diversity to create better-quality products and services. Also called “diversity and inclusion (D&I),” which refers to receptivity to diversity and incorporating diverse opinions and ideas rather than the simple pursuit of variety, and also encompasses the concept of raising organizational value.

**Talent management**
Talent management is the human resource strategy by which we identify and develop leaders and highly skilled specialists at an early stage. It is also the means by which we improve the skills and enhance the motivation of employees throughout the Company, with the aim of realizing our corporate strategy and catalyzing the creation of innovation. Each organization at Chugai has formulated a long-term human resource development plan and is building a talented pool of leaders.

**Terms Related to Human Resources**

**Work-life balance**
A leading biotechnology company headquartered in Basel, Switzerland. With business operations in more than 100 countries, the Roche Group contributes to medicine in a wide range of fields through its two business segments: pharmaceuticals and diagnostics. Central to the Roche Group’s strategy is PHC, the approach of selecting the most appropriate treatment by using biomarkers and diagnostic/genetic tests including genomic profiling to identify patients most likely to show a significant response to a particular drug. The Roche Group’s sales in 2019 were 61.5 billion Swiss francs.

**Roche Diagnostics K.K.**
The Japanese subsidiary of the Roche Group’s diagnostics division. Established in 1998, Roche Diagnostics K.K. provides a wide range of innovative diagnostic solutions, including in-vitro diagnostics and diagnostic equipment and research reagents and related equipment.

**Genentech Inc.**
A leading biotechnology company headquartered in South San Francisco, California. Genentech has been a member of the Roche Group since 1990.

**Foundation Medicine Inc. (FMI)**
FMI was established in Massachusetts, U.S.A. in 2010. In 2015, Roche took a majority stake, and then acquired the remaining outstanding shares in 2018 to make FMI a wholly-owned subsidiary. Chugai established the FMI business as a specialized unit in October 2018 to promote uptake and product value maximization of FMI’s “Comprehensive Genomic Profiling Service” in Japan.
Network (As of April 1, 2020)

Chugai Pharmaceutical

Head Office
Nihonbashi Mitsui Tower (Reception 15F)
2-1 Nihonbashi-Murumachi,
Chuo-ku, Tokyo 103-8324 Japan
Tel +81-(0)3-3281-6611 (main switchboard)
URL: https://www.chugai-pharm.co.jp/english/

Research Laboratories
Fuji Gotemba Research Laboratories
1-135 Komakado, Gotemba City,
Shizuoka Pref. 412-8513 Japan
Tel +81-(0)550-87-3411

Kamakura Research Laboratories
200 Kajiwara, Kamakura City,
Kanagawa Pref. 247-8530 Japan
Tel +81-(0)467-47-2260

Ukima Research Laboratories
5-5-1 Ukima, Kita-ku,
Tokyo 115-8543 Japan
Tel +81-(0)3-3968-6111

Plants
(Chugai Pharma Manufacturing Co., Ltd.)

Ukima Plant
5-5-1 Ukima, Kita-ku, Tokyo 115-8543 Japan
Tel +81-(0)3-3968-6200

Fujiieda Plant
2500 Takaayagi, Fujiieda City,
Shizuoka Pref. 426-0041 Japan
Tel +81-(0)54-635-2311

Utsunomiya Plant
163-5 Koyohara-Kogyodanchi, Utsunomiya City,
Tochigi Pref. 321-3231 Japan
Tel +81-(0)28-667-7611

Branches
Hokkaido Branch
8F Nihon Seimei Sapporo Bldg., 4-1-1
Kita-sando-Nishi, Chuo-ku, Sapporo City,
Hokkaido 060-0003 Japan
Tel +81-(0)11-271-5311

Miyagi and Yamagata Branch
3F Sankyo Sendai Bldg., 1-12-7 Honcho,
Aoba-ku, Sendai City,
Miyagi Pref. 980-0014 Japan
Tel +81-(0)20-225-8551

Ibaraki Branch
8F Nissei Mito Bldg., 2-2-27 Izumi-cho,
Mito City, Ibaraki Pref. 310-0026 Japan
Tel +81-(0)29-227-1951

Gunma and Tochigi Branch
9F East Tower, 16-11 Sakae-cho,
Takasaki City, Gunma Pref. 370-0841 Japan
Tel +81-(0)27-321-6511

Niigata Branch
8F Niigata Ekima Bldg., 3-2-3 Benten,
Chuo-ku, Niigata City,
Niigata Pref. 950-0901 Japan
Tel +81-(0)25-247-7331

Nagano and Yamanashi Branch
8F Keshin Matsumoto Fukushi Bldg.,
2-5-2 Fukushi, Matsumoto City,
Nagano Pref. 390-0815 Japan
Tel +81-(0)20-263-1373

Tokyo Branch
Tokyo Branch 1
Tokyo Branch 2
Tokyo Branch 3
17F Osaki Bright Core Bldg.,
5-5-15 Kita-shinagawa, Shinagawa-ku,
Tokyo 141-0001 Japan
Tel +81-(0)3-5449-6760

Nagoya Branch
5F Fujimi Hainesu Bldg., 2-7-5 Fujimi-cho,
Chubu-ku, Chiba Pref. 260-0015 Japan
Tel +81-(0)43-224-1511

Kidogawa Branch
3F Yokohama East Square, 1-4 Kinkou-cho,
Kanagawa Pref., 221-0056 Japan
Tel +81-(0)43-224-1511

Yokohama Branch
5F Yokohama East Square, 1-4 Kinkou-cho,
Kanagawa Pref. 221-0056 Japan
Tel +81-(0)45-450-7670

Atsugi Branch
8F Nihon Seimei Hon-atsugi Bldg.,
2-2-7 Asahi-cho, Atsugi City,
Kanagawa Pref. 220-0015 Japan
Tel +81-(0)467-229-2700

Aichi Branch
KDX Sakurado-cho Bldg., 3-20-17
Marunouchi, Naka-ku, Nagoya City,
Aichi Pref. 460-0002 Japan
Tel +81-(0)52-961-8511

Gifu and Mie Branch
11F Nohji Nissei Bldg., 2-8 Hashimoto-cho,
Gifu City, Gifu Pref. 500-8856 Japan
Tel +81-(0)58-252-7400

Shizuoka Branch
4F Nissei Shizuoka Ekima Bldg.,
59-7 Kurogane-cho, Aoi-ku, Shizuoka City,
Shizuoka Pref. 420-0851 Japan
Tel +81-(0)54-252-9125

Kyoto and Shiga Branch
7F Karasuma Chuo Bldg., 659 Teearaimizu-cho,
Nishikikoj-igari, Karasuma-dori, Nagakyo-ku,
Kyoto City, Kyoto 604-8152 Japan
Tel +81-(0)7-512-6090

Hokuriku Branch
(Ishikawa/Toyama/Fukui)
13F Visage, 16-1 Showa-cho, Kanazawa City,
Ishikawa Pref. 920-0856 Japan
Tel +81-(0)76-232-6766

Osaka-Kita Branch
13F Uemura Nissel Bldg.,
3-3-31 Miyahara, Yodogawa-ku,
Osaka City, Osaka Pref. 532-0003 Japan
Tel +81-(0)6-6350-6359

Osaka-Minami Branch
14F Portas Center Bldg.,
4-45-1 Ebisujima-cho, Sakae-ku,
Sakae, Osaka Pref. 590-0885 Japan
Tel +81-(0)6-72-223-1575

Nara and Wakayama Branch
5F Nara Center Bldg., 7-1-33 Omiya-cho,
Sakae, Nara City, Nara Pref. 630-8115 Japan
Tel +81-(0)742-35-6101

Hyogo Branch
9F Meji Yasuda Seimei Kobe Bldg.,
3-3-6 Islandori-dori, Chuo-ku, Kobe City,
Hyogo Pref. 651-0086 Japan
Tel +81-(0)7-241-6851

Hiroshima Branch
6F Nissei Hiroshima Bldg.,
7-32 Nakamachi, Naka-ku, Hiroshima City,
Hiroshima Pref. 730-0037 Japan
Tel +81-(0)82-543-6100

Yamaguchi Branch
10F Square Shintamaguchi,
2-21 Ogori-kogame-machi, Yamaguchi City,
Yamaguchi Pref. 754-0021 Japan
Tel +81-(0)83-972-1666

Tottori and Shimane Branch
6F Yonago Shoko Kaisho Kaikan,
2-204 Kamo-cho, Yonago City,
Tottori Pref. 683-0263 Japan
Tel +81-(0)89-34-3521

Okayama Branch
4F Lit City Bldg., 15-1 Ekimoto-machi, Kita-ku,
Okayama City, Okayama Pref. 700-0024 Japan
Tel +81-(0)86-214-3760

Kagawa and Tokushima Branch
7F Ichigo Takamatsu Bldg.,
2-2-7 Kotobuki-cho, Takamatsu City,
Kagawa Pref. 760-0023 Japan
Tel +81-(0)87-81-6988

Ehime and Kouchi Branch
8F Tajii Seimei Matsuyama Bldg.,
4-1-1 Ichiban-cho, Matsuyama City,
Ehime Pref. 790-0001 Japan
Tel +81-(0)89-945-3600

Fukuoka Branch
8F Echo Bldg., 2-13-34 Hakataeki-higashi,
Fukuoka City, Fukuoka Pref., 812-0013 Japan
Tel +81-(0)9-93-91-2900

Nagasaki and Saga Branch
Nagasaki Ekima Daichi Seimei Bldg.,
2-3 Nishizaka-machi, Nagasaki City,
Nagasaki Pref. 850-0051 Japan
Tel +81-(0)95-825-4772

(Ishikawa/Toyama/Fukui)
Shareholder Information (As of December 31, 2019)

Major Shareholders

<table>
<thead>
<tr>
<th>Name</th>
<th>Number of Shares Held (Thousands)</th>
<th>Percentage of Voting Rights (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche Holding Ltd</td>
<td>335,223</td>
<td>61.24</td>
</tr>
<tr>
<td>The Master Trust Bank of Japan, Ltd. (Trust Account)</td>
<td>30,258</td>
<td>5.52</td>
</tr>
<tr>
<td>JP MORGAN CHASE BANK 380055</td>
<td>16,388</td>
<td>2.99</td>
</tr>
<tr>
<td>Japan Trustee Services Bank, Ltd. (Trust Account)</td>
<td>16,075</td>
<td>2.93</td>
</tr>
<tr>
<td>STATE STREET BANK AND TRUST COMPANY 505001</td>
<td>10,537</td>
<td>1.92</td>
</tr>
<tr>
<td>Japan Trustee Services Bank, Ltd. (Trust Account 7)</td>
<td>4,756</td>
<td>0.86</td>
</tr>
<tr>
<td>Japan Trustee Services Bank, Ltd. (Trust Account 5)</td>
<td>4,230</td>
<td>0.77</td>
</tr>
<tr>
<td>STATE STREET BANK WEST CLIENT - TREATY 505234</td>
<td>3,998</td>
<td>0.73</td>
</tr>
<tr>
<td>SSBTC CLIENT OMNIBUS ACCOUNT</td>
<td>3,795</td>
<td>0.69</td>
</tr>
<tr>
<td>NORTHERN TRUST CO. (AVFC) SUB A/C AMERICAN CLIENTS</td>
<td>3,528</td>
<td>0.64</td>
</tr>
</tbody>
</table>

Note: 12,162,354 shares of treasury stock held by the Company are not included in the above breakdown of major shareholders.

Stock Price Information

<table>
<thead>
<tr>
<th>Stock Price Information (From January 1, 2019 to December 31, 2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price</td>
</tr>
<tr>
<td>Low</td>
</tr>
<tr>
<td>First Quarter</td>
</tr>
<tr>
<td>Second Quarter</td>
</tr>
<tr>
<td>Third Quarter</td>
</tr>
<tr>
<td>Fourth Quarter</td>
</tr>
</tbody>
</table>

Share Performance1 with Stock Indices

- Trading volume (right scale)
- CHUGAI (left scale)
- TOPIX-17 PHARM Index2 (left scale)
- Nikkei Average Index (left scale)

Note: 1. Closing price on December 30, 2014 = 100
2. A capitalization-weighted index that consists of pharmaceutical companies on the Tokyo Stock Exchange, First Section.

Share Price Indicators

<table>
<thead>
<tr>
<th>Price/Earnings Ratio</th>
<th>Price/Book Ratio</th>
<th>Dividend Yield</th>
</tr>
</thead>
<tbody>
<tr>
<td>Year-end share price/Basic net income per share (Times)</td>
<td>50.00</td>
<td>6.00</td>
</tr>
<tr>
<td>40.00</td>
<td>37.86</td>
<td>4.00</td>
</tr>
<tr>
<td>30.00</td>
<td>34.19</td>
<td>2.00</td>
</tr>
<tr>
<td>20.00</td>
<td>37.73</td>
<td>2.94</td>
</tr>
<tr>
<td>10.00</td>
<td>35.02</td>
<td>4.56</td>
</tr>
<tr>
<td>0.00</td>
<td>0.00</td>
<td>6.46</td>
</tr>
</tbody>
</table>

Dividends per share/Year-end share price (Times) | 2.50 |
| 1.50 | 1.37 | 1.55 | 1.35 | 1.93 |
Corporate Overview
(As of December 31, 2019)

Company Name: Chugai Pharmaceutical Co., Ltd.
Year of Foundation: 1925
Year of Establishment: 1943
Address: 2-1-1, Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-8324 Japan
Stated Capital: ¥73,202 million
Number of Employees: 7,394 (Consolidated)
Number of Shares Issued of Common Stock: 559,685,889
Number of Shareholders: 19,752
Stock Listing: Tokyo Stock Exchange, First Section
Fiscal Year-End: December 31
General Meeting of Shareholders: March
Transfer Agent: Mitsubishi UFJ Trust and Banking Corporation

For further information, please contact:
Corporate Communications Dept.
Tel: +81-(0) 3-3273-3313
Fax: +81-(0) 3-3281-6607
E-mail: ir@chugai-pharm.co.jp

Editorial Policy
This integrated report is structured to encourage dialogue with shareholders, investors and other stakeholders. We hope it will be useful in sharing value with you.

Scope of This Report
This report presents information on Chugai Pharmaceutical Co., Ltd. and its consolidated subsidiaries. In some places, however, it gives data specifically pertaining to Chugai Pharmaceutical Co., Ltd.

Timeframe
The basic timeframe for this report is the financial reporting period of January to December 2019. However, in view of the importance of providing the latest information available, some information relating to activities that occurred in 2020 is included, mainly in research and clinical development data.

Information in This Report
This report presents information that Chugai believes to be important given its significance in building Chugai’s corporate value over the short, medium and long term, and its degree of impact on stakeholders.

Reference Guidelines
The content of this report is focused on value creation, using as reference The International Integrated Reporting Framework issued by the International Integrated Reporting Council (IIRC) and Guidance for Integrated Corporate Disclosure and Company-Investor Dialogue for Collaborative Value Creation compiled by the Ministry of Economy, Trade and Industry of Japan. Sustainability information was prepared with reference to Environmental Reporting Guidelines 2018 issued by the Ministry of the Environment of Japan, the GRI Sustainability Reporting Standards of the Global Reporting Initiative (GRI), and the Final Report on Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).

As the result of a third-party audit, FTSE Russell (a registered trademark of FTSE International Limited and Frank Russell Company) hereby attests that Chugai satisfies the conditions of listing on the FTSE Blossom Japan Index and has been made a constituent stock of such index. The FTSE Blossom Japan Index was created by FTSE Russell, a global index provider, and has been designed to measure the performance of Japanese companies demonstrating excellent environmental, social, and governance (ESG) practices. The FTSE Blossom Japan Index is widely used in the creation and evaluation of sustainable investment funds and other financial products. The inclusion of Chugai Pharmaceutical Co., Ltd. in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of Chugai Pharmaceutical Co., Ltd. by MSCI or any of its affiliates. The MSCI indices are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service marks of MSCI or its affiliates.

Management Participation in Planning
We consider this report to be an important tool for dialogue on Chugai’s value creation. In producing it, Representative Director and Deputy Chairman Moto Ueno (left photo) and Chief Financial Officer (CFO) Toshiaki Itagaki (right photo) engaged in discussions on its concept, structure, content and design at a number of meetings and took responsibility up to its completion. Interviewees and confirmation of the content were conducted with Representative Director, Chairman & CEO Tatsuro Kosaka and Representative Director, President & Chief Operating Officer (COO) Osamu Okuda, in addition the two aforementioned officers.

Positioning of the Report within the Company
The level of awareness of this report is high within the Company, and in addition to discussions held among persons in charge in each division during its production process, it is used in a wide range of applications including introduction at strategy briefings for employees and use in new graduate recruiting.